80ACTIVITIES
1ORGS REPRESENTED
41BILLS
Organizations represented
1Orgs whose LD-2 filings list Praneel as an active lobbyist, sorted by activity volume.
Bills they file on
41H.R. 167219 mentions
H.R. 126219 mentions
S. 86417 mentions
S. 109716 mentions
S. 52616 mentions
S. 52716 mentions
S. 109616 mentions
S. 109516 mentions
S. 70516 mentions
H.R. 616615 mentions
S. 104115 mentions
S. 265815 mentions
S. 83215 mentions
S. 130215 mentions
S. 93215 mentions
+ 26 more bills referenced in their activities
Topics in Filings
365Policy topics Praneel files on across all their LD-2 activities.
Medical Countermeasure Priority Review Voucher Reauthorization×115
Development and Procurement×72
Funding for Strategic National Stockpile×71
Antimicrobial Resistance×69
FY 2026 Appropriations for Agencies×68
Biodefense/Biomedical/Emergency Preparedness Research×68
Centers for Disease Control and Prevention×67
Health Resources and Services Administration×67
HHS Office of Infectious Disease and HIV/AIDS Policy×65
Administration for Strategic Preparedness and Response×56
Biomedical Advanced Research and Development Authority×56
CMMI: GLOBE and GUARD Models×56
Show all 365 topics (+353 more) ▾
Development and Procurement Issues×54
National Coverage Determination×54
Pandemic Preparedness×53
Stop STALLING Act×52
R&D Funding for Medical Countermeasures×49
Clinical Trial Data in China×48
Pediatric Priority Review Voucher×43
Most Favored Nation Drug Pricing Proposals×43
Preserve Access to Affordable Generics and Biosimilars Act×42
Food & Drug Administration×42
International Pricing Policies×42
MCM PRV Reauthorization×41
Prescription Pricing for the People Act×40
Pharmacy Benefit Manager Transparency Act×38
CMMI Authority×38
Risky Research Review Act×37
FY 2025 Appropriations×35
Maintaining Investments and New Innovation×35
Drug Supply Chain Management×35
Supply Chain Issues×35
Biosimilar Red Tape Elimination Act×34
Lowering Drug Costs for American Families Act×34
SAFE STEP Act×34
Funding for Women's Health Research×33
Medicare Drug Price Negotiation Act×33
Modernizing and Ensuring PBM Accountability×33
Drug Pricing×32
Medicaid VBPs for Patients×32
Increasing Transparency in Generic Drug Application×31
Pandemic Preparedness -R&D Funding for Medical Countermeasures×30
FY 2026 Appropriations for Specific Issues×30
Centers for Medicare and Medicaid×28
National Institutes of Health×28
Funding for Section 317×28
340B Rebate Rule×28
National Defense Authorization Act 2027×28
Big Savings Act×28
Interagency Patent Coordination and Improvement Act×27
FY 2026 Appropriations×25
Vaccine Injury Compensation Program×23
Mandating Exclusive Review of Individual Treatments×21
Advanced Research Projects Agency for Health×20
Bio COMPETES×20
Affordable Prescriptions for Patients Act×20
Prescription Drug User Fee Act×20
BIOSECURE Act×19
CICP×19
Interchangeability and Pharmacy Substitution×19
Promising Pathway Act×19
Quality & Distribution×19
Advanced Manufacturing×19
Drug Shortages×19
Supply Chain Integrity and Traceability×19
Patient Cost-Sharing and Implementation×19
Alternative Payment Arrangements for Gene Therapies×19
Drug Benefit Design×19
National Defense Authorization Act×19
Support of Patient Premiums and Cost-Sharing Obligations×19
Adult Immunization×19
MCM Manufacturing & Capacity×19
Vaccine Safety net and Vaccine Infrastructure×19
Value of Vaccines and Vaccine Confidence×19
VICP Loopholes×19
Access to Innovative Treatments Act×19
American Privacy Rights Act×18
Medication Affordability and Patient Integrity Act×18
Accelerated Approval Artificial Intelligence×18
MCM PRV Program Reauthorization×18
WHO Pandemic Preparedness Accord Biosimilars×18
Pricing and Rebates×18
Medicare Part B Physician-Administered Products×18
Patient Cost-Sharing and Smoothing×18
Maternal Immunization×18
Vaccine and Antimicrobial Resistance Product Development and Incentives×18
Program Implementation & Oversight×18
Orphan Drug Tax Credit×18
Vaccines and Infectious Diseases×18
Pandemic Flu×18
Reimbursement Cell & Gene Therapy×17
Average Manufacturer Price Calculations×17
Value-based Contracting and Communications×17
State Strategic Stockpile Act×17
Vaccine Access & Compensation×17
Alternative Funding Programs×17
Influenza Planning & Response×17
Project Bioshield×17
FDA Hiring Flexibility×17
DRUG Act×17
FDA Modernization×17
Act 3.0 Medicaid×17
Innovation in Pediatric Drugs Act×17
Retaining Access and Restoring Exclusivity×17
Step Therapy×17
Let Injured Americans Be Legally Empowered×17
MCM R&D Incentives×17
Vaccine Injury Compensation Modernization×17
Vaccine Quality Measure×17
Vaccine Safety×17
Diversity & Inclusion×16
Disease X Act×16
Gain of function×16
SAFE Risky Research Act×16
Vaccine Access Improvement Act×16
Generic Drug Entry×16
Generic Drug Application Review Reforms×16
Incentives for Generic Entry Issues×16
Funding for Medical Countermeasures×16
House GOP RFI on Supply Chain×15
White House National Biodefense Strategy×15
Coverage and Reimbursement×15
Section 317 Immunization Program×15
Vaccine Injury Compensation Program 340B Drug Discount Program×15
Compounding Pharmacies×15
Contract Manufacturing Ecosystem in the United States×15
Access to Innovative Treatments×15
PASTEUR ACT×15
Biosecurity Modernization×15
WHO Pandemic Preparedness Accord Pandemic Preparedness×15
VICP/CICP Antimicrobial Resistance Biodefense Research×15
CMMI Models: GLOBE and GUARD×14
Biosimilars Competition×14
Purple Book Draft×14
Consumer Data Privacy and Security Act×14
Data Privacy Working Group Draft×14
Diagnostics and Personalized Medicine Regulation and Oversight×14
Decentralized Clinical Trials Drug Evaluation and Review×14
PDUFA VII Implementation×14
PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14
CMMI×14
NSC/OSTP priorities×14
Nucleic acid synthesis security and biotechnology governance×14
Non-Opioid Analgesics Orphan Drug Issues×14
Pediatric Priority Review Voucher Pandemic Preparedness×14
Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14
VICP/CICP Biodefense Research×14
CDC Reform×14
ORPHAN Cures Act×9
FDA Approvals×8
Guidance, & Regulations×8
Restrictions on Intellectual Property Rights×8
Farm Bill Reauthorization×7
Value-Based Purchasing×7
Monoclonal Antibody Coverage and Utilization×7
Gene Editing×7
MCM PRV Program×7
Tropical Disease Priority Review Voucher×6
Temporarily Refundable R&D Credit×6
HHS Reorganization×6
ASPR×6
Efficient Science-Based Review of Biotech Products×5
Genetically Engineered×5
TRIPS Waiver×5
Executive Order on Access to Affordable Life-Saving Medications×5
COVID-19 Pricing Related Provisions×5
Strengthening Innovation in Medicare and Medicaid Act×5
SUPPORT Act×5
WHO Pandemic Preparedness Accord×5
National Institute of Health×5
Prescription Drug Price Relief Act×5
BARDA×5
International Consistency of Regulations×4
Rural Development×4
Food and Drug Administration, and Related Agencies Appropriations Act×4
FY 2026 Appropriations Funding for Antimicrobial Resistance×4
Bill to address patent thickets×4
Biosimilar Copay×4
Decentralized Clinical Trials×4
Safe, and Secure American Bioeconomy×4
Patent Thickets×4
Coverage of Accelerated Approval Products×4
Give Kids a Chance Act×4
HELP Copays Act×4
Lower Costs×4
Protected Classes×4
Executive Order on Achieving Efficiency Through State and Local Preparedness×4
340B Accountability Act×4
Creating Hope Reauthorization×4
Emerging New Threats and×4
Finding Orphan-Disease Remedies with Antifungal Research and Development×4
National Defense Authorization Act 2026×4
Farm Bill×3
China Biotechnology Regulations×3
Climate Issues & impact on the agriculture and food sectors×3
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance×3
Reasonable Pricing Clauses in BARDA Contracts×3
House GOP RFI on Data Privacy×3
COVID-19 Lessons Learned×3
PBM Reform×3
MCM PRV×3
Non-Opioid Analgesics×3
Pediatric Priority Review Voucher Program×3
Medical Countermeasures PRV Reauthorization×3
PPRV×3
PROTECT 340B Act×3
SUSTAIN 340B Act×3
Medicare Negotiation and Competitive Licensing Act×3
Orphan Drug Issues×3
ASPR FY 2026 Appropriations for Specific Issues×3
Avian Flu×2
Farm to Fly Act×2
Food & Ag National Security×2
EPA proposed revisions to regulations×2
USMCA Review×2
Biomass Crop Assistance, and Biorefineries×2
Office of Biopesticides and Pollution Prevention Division×2
Biotechnology and Agriculture Trade Program×2
Farm Bill Programs Energy Title IX×2
NextGen Aircraft Technology×2
Fuels & Metrics×2
Prohibiting Adversarial Patents Act×2
Protecting Americans Data from Foreign Adversaries Act×2
Patent Eligibility Restoration Act×2
WHO Pandemic Preparedness Accord World Intellectual Property Office×2
Treaty on Intellectual Property×2
Genetic Resources, and Associated Traditional Knowledge World Trade Organization×2
340B Drug Discount Program×2
Biosecurity Infrastructure for Operational×2
NDAA×2
MINI Act×2
Climate Change×2
FDA Hiring Flexibility Drug Importation Drug Manufacturing×2
VICP×2
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×2
Medicaid Drug Rebate Program Rule×2
Coverage and Reimbursement Orphan Drug Issues×2
Administration Rebate Rule×2
More Cures Act×2
Countermeasures Injury Compensation Program×2
Vaccine Safety and Quality×2
Biodefense Research×2
Funding for Biodefense/Biomedical/Emergency Preparedness Research×2
USDA×2
APHIS×2
Project Bio Shield×2
Improving Data Accessibility Through Advancements×2
Drug Evaluation and Review×2
Drug Importation Drug Manufacturing×2
Stronger Patents Act×2
Most Favored Nation×2
Protecting Patient Access to Cancer and Therapies×2
Fair Prescription Drug Prices for Americans Act×2
Global Fairness in Drug Pricing Act×2
More Transparency Act×2
Family Vaccine Protection Act×2
National Institutes of Health FY 2026 Appropriations for Specific Issues×2
General Climate Change×1
Mexico Decree Banning Genetically Modified Corn Funding for the USDA×1
FY 2026 Appropriations Genetically Engineered×1
EPA Regulatory Approach to Gene Editing×1
FDA Proposed guidance on Gene Editing×1
USDA Regulatory Approach to Gene Editing Interagency Coordination×1
DOE and USDA Interagency Research Act×1
Regulatory Treatment of Gene Edited Products×1
Regulatory Treatment of Biostimulants United States-Mexico-Canada Agreement×1
Avian Flu Farm Bill×1
Funding for Antimicrobial Resistance×1
FY 2026 Appropriations Pandemic Preparedness×1
Bioenergy Technology Office×1
Environmental Energy R&D×1
Pharmacy Benefit Managers Artificial Intelligence×1
Patentability of AI-Aided inventions Bayh-Dole Act/Tech Transfer×1
Invent Here×1
Make Here Act×1
Bayh-Dole Act×1
March-In Rights×1
Reasonable Pricing Clause Compulsory Licensing Data Privacy Issues×1
Inventor Diversity for Economic Advancement×1
Drug Patenting×1
Title 35 to Address Infringements of Patents Claiming Biological Products×1
Protecting Consumer Access to Generic Drugs Act×1
FTC Orange Book Delisting Initiative×1
Orange Book Listing×1
PTO Proposed Rules on Terminal Disclaimer Practice×1
China Patent Reform×1
Patent Litigation Reform×1
USPTO Request for Comments: Experimental Use Defense 89 Fed×1
Reg 53963 Patenting of Biological Inventions×1
Section 101 Modernization×1
RESTORE Patent Rights Act×1
World Health Organization×1
Program & Oversight×1
American Pandemic Preparedness Plan×1
FY 2026 Appropriations Data Privacy×1
Clinical Trial Diversity Drug Evaluation and Review×1
Compounded Medicines×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
Orphan Drug Tax Credit Pandemic Preparedness×1
Womens Health Research Pandemic Preparedness×1
BSUFA Negotiations×1
General Cell & Gene Therapy×1
FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1
General Diversity & Inclusion×1
Clinical Trial Diversity×1
General Drug Evaluation and Review×1
Compounded Medicines Drug Patenting×1
FY2025 Appropriations×1
PBN Reform×1
International Reference Pricing Foreign Drug Data Protection Laws×1
Regulatory Harmonization Funding for Antimicrobial Resistance×1
FY 2026 Appropriations International Reference Pricing Issues×1
Medicaid Drug Rebate Program×1
Innovation and Pediatric Drugs Act×1
CFIUS and Foreign Investment Drug Importation Drug Pricing×1
EU Ag-Biotech Policies×1
International Consistency of Regulation for Gene Edited Products×1
Korea Biotechnology Regulations×1
B5 Coalition on Supply Chain Resiliency×1
Medical Supply Chain Resiliency Act×1
Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement×1
Ag-Biotech Provisions×1
IP Provisions World Health Organization×1
Dept of Interior×1
Dept of Energy×1
Dept of Transportation×1
USDA Avian Flu×1
Foreign Animal Disease Efforts to expand the Bio Economy & Bio Manufacturing×1
Foreign Animal Disease Farm Bill×1
Department of Energy×1
Department of Transportation×1
USDA FY 2026 Appropriations for Specific Issues×1
Environment and Energy R&D×1
Renewable Materials/BIO-based Products×1
BARDA FY 2026 Appropriations for Specific Issues×1
Section 317 Immunization Program 340B Drug Discount Program×1
Accelerated Approval Access to non-human Primates×1
Climate Change Data Privacy×1
PDUFA×1
FDA Reform×1
Compounding & Counterfeit Medicines Drug Patenting×1
Rare Disease Pilot Program Pandemic Preparedness×1
End Price Gauging for Medications Act×1
SMART Prices Act×1
Countermeasure Injury Compensation Fund Amendment Act×1
VICP CICP×1
HHS Reorganization Pandemic Preparedness×1
National Institute of Health FY 2026 Appropriations for Specific Issues×1
Reimbursement Cell & Gene Therapy Data Privacy×1
Clinical Trial Modernization×1
One Big Beautiful Bill Act×1
Drug Rebate Program Rule×1
HHS Reorganization CDC Reform×1
340B ACCESS Act×1
Synthetic Nucleic Acid Synthesis Screening×1
PDUFA VIII Negotiations×1
Drug Manufacturing×1
Biologics Competition Act×1
Enhanced Access to Affordable Medicines Act×1
Most Favored Nation Pricing Opioid Crisis×1
Reimbursement and Coverage of Innovative Products×1
Administrative Rebate Rule×1
MCM PRV Program CDC Reform×1
Issue mix
LDA general-issue codes weighted by activity count.
Budget/Appropriations18
Health Issues18
Homeland Security18
Medical/Disease Research/Clinical Labs18
Agriculture2
Animals2
Copyright/Patent/Trademark1
Food Industry (safety, labeling, etc.)1
Medicare/Medicaid1
Trade (domestic/foreign)1